Drug Profile
64Cu MeCOSar Octreotate - Clarity Pharmaceuticals
Alternative Names: 64-Cu-SARTATE; 64Cu-MeCOSar-Octreotate; copper-64 labelled MeCOSar-Tyr3-octreotateLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Clarity Pharmaceuticals
- Class Diagnostic agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Neuroendocrine tumours
- Phase I/II Meningioma; Neuroblastoma
Most Recent Events
- 16 Feb 2021 Clarity Pharmaceuticals initiates a phase II trial for Neuroendocrine tumours (Diagnosis, In Adults, In the elderly) in Australia (IV) (NCT04438304)
- 09 Sep 2020 64Cu MeCOSar Octreotate receives Rare Pediatric Disease Designation for Neuroblastoma in USA
- 17 Jul 2020 Phase-I/II clinical trials in Neuroblastoma (In adults, In children, In the elderly) in USA (Parenteral) (NCT04023331)